Focused On-demand Library for Neurogenic locus notch homolog protein 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P46531

UPID:
NOTC1_HUMAN

ALTERNATIVE NAMES:
Translocation-associated notch protein TAN-1

ALTERNATIVE UPACC:
P46531; Q59ED8; Q5SXM3

BACKGROUND:
The Neurogenic locus notch homolog protein 1, with alternative name Translocation-associated notch protein TAN-1, is crucial for regulating cell fate, angiogenesis, and immune cell maturation. It acts by forming a transcriptional activator complex, influencing gene expression related to cell differentiation and survival. This protein also plays a role in neurogenesis and somite formation, underscoring its importance in embryonic development.

THERAPEUTIC SIGNIFICANCE:
The association of Neurogenic locus notch homolog protein 1 with diseases such as aortic valve disease 1 and Adams-Oliver syndrome 5 underscores its therapeutic significance. Targeting this protein could lead to innovative treatments for these conditions, emphasizing the importance of further research into its functions and mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 168 of 8789